NeoGenomics
Receive regular headline summaries whenever high-quality news is generated for NeoGenomics. We'll never share your email address with others.
Selected Headlines
| Date | Headline (link) | Source | Relevant Snippet |
|---|---|---|---|
| 6/6/2022 | NeoGenomics (NASDAQ:NEO) Coverage Initiated by Analysts at Piper Sandler | dispatchtribunal.com | Piper Sandler started coverage on shares of NeoGenomics ( NASDAQ:NEO – Get Rating ) in a research report report published on Thursday morning, The Fly reports. The brokerage issued an overweight rating and a $13.00 target price on the medical research company’s stock.NEO has been the subject of several other research reports. Needham & Company LLC decreased their price target on shares of NeoGenomics from $29.00 to $19.00 and set ... |
| 6/6/2022 | NeoGenomics (NASDAQ:NEO) Coverage Initiated by Analysts at Piper Sandler - Mayfield Recorder | Mayfield Recorder | Piper Sandler started coverage on shares of NeoGenomics ( NASDAQ:NEO – Get Rating ) in a research report report published on Thursday morning, The Fly reports. The brokerage issued an overweight rating and a $13.00 target price on the medical research company’s stock.NEO has been the subject of several other research reports. Needham & Company LLC decreased their price target on shares of NeoGenomics from $29.00 to $19.00 and set ... |
| 6/6/2022 | Barclays PLC Has $5.34 Million Stake in NeoGenomics, Inc. (NASDAQ:NEO) - Ticker Report | Ticker Report | Barclays PLC raised its stake in shares of NeoGenomics, Inc. ( NASDAQ:NEO – Get Rating ) by 13.5% in the fourth its most recent 13F filing with the SEC. The fund owned 156,500 shares of the medical research company’s stock after purchasing an additional 18,587 Barclays PLC’s holdings in NeoGenomics were worth $5,341,000 as of its most recent SEC filing.Other hedge funds also recently added to or reduced ... |
| 6/6/2022 | Barclays PLC Purchases 18,587 Shares of NeoGenomics, Inc. (NASDAQ:NEO) | zolmax.com | Barclays PLC grew its position in NeoGenomics, Inc. ( NASDAQ:NEO – Get Rating ) by 13.5% in the fourth quarter, according to its most recent filing with the SEC. The fund owned 156,500 shares of the medical research company’s stock after acquiring an additional 18,587 shares during the period. Barclays PLC owned 0.13% of NeoGenomics worth $5,341,000 as of its most recent filing with the SEC.Other institutional investors and ... |
| 6/5/2022 | Mirova Buys 16,194 Shares of NeoGenomics, Inc. (NASDAQ:NEO) - Slater Sentinel | slatersentinel.com | Mirova grew its holdings in NeoGenomics, Inc. ( NASDAQ:NEO – Get Rating ) by 33.7% in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 64,247 shares of the medical research company’s stock after buying an additional 16,194 shares during the period. Mirova owned approximately 0.05% of NeoGenomics worth $2,192,000 as of its most recent filing with the Securities & Exchange Commission ... |
| 6/5/2022 | Mirova Acquires 16,194 Shares of NeoGenomics, Inc. (NASDAQ:NEO) | rivertonroll.com | Mirova lifted its position in shares of NeoGenomics, Inc. ( NASDAQ:NEO – Get Rating ) by 33.7% in the fourth quarter, HoldingsChannel reports. The fund owned 64,247 shares of the medical research company’s stock after buying an additional 16,194 shares during the period. Mirova’s holdings in NeoGenomics were worth $2,192,000 at the end of the most recent quarter.Several other hedge funds have also recently added to or reduced ... |
| 6/3/2022 | NeoGenomics Receives CAP Certification in their Suzhou China Pharma Services Laboratory | healthtechnologynet.com | NeoGenomics Receives CAP Certification in their Suzhou China Pharma Services LaboratoryCAP Certification Expands Global Strategic Capabilities Supporting Biopharma R&DFORT MYERS, FL / ACCESSWIRE / June 3, 2022 / NeoGenomics , Inc. (Nasdaq:NEO), a leading provider of oncology testing and global contract research services, has successfully received their CAP certification with zero deficiencies. This certification is the next step in NeoGenomics offering its global pharmaceutical partners the much-needed option to ... |
| 6/3/2022 | Piper Sandler Initiates Coverage on NeoGenomics (NASDAQ:NEO) | baseballnewssource.com | Piper Sandler began coverage on shares of NeoGenomics ( NASDAQ:NEO – Get Rating ) in a report published on Thursday morning, The Fly reports. The firm issued an overweight rating on the medical research company’s stock.Several other brokerages also recently issued reports on NEO. Zacks Investment Research downgraded shares of NeoGenomics from a hold rating to a sell rating in a research note on Wednesday, May 4th. Stephens downgraded ... |
| 6/3/2022 | NeoGenomics (NASDAQ:NEO) Coverage Initiated by Analysts at Piper Sandler | zolmax.com | Piper Sandler initiated coverage on shares of NeoGenomics ( NASDAQ:NEO – Get Rating ) in a research note published on Thursday morning, The Fly reports. The brokerage issued an overweight rating on the medical research company’s stock.Several other equities research analysts also recently issued reports on NEO. StockNews.com upgraded shares of NeoGenomics to a sell rating in a research note on Thursday, May 12th. Craig Hallum decreased their price ... |
| 6/3/2022 | Charles Schwab Investment Management Inc. Has $30.59 Million Position in NeoGenomics, Inc. (NASDAQ:NEO) | zolmax.com | Charles Schwab Investment Management Inc. boosted its holdings in NeoGenomics, Inc. ( NASDAQ:NEO – Get Rating ) by 2.1% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 896,587 shares of the medical research company’s stock after buying an additional 18,538 shares during the period. Charles Schwab Investment Management Inc. owned approximately 0.73% of NeoGenomics worth $30,593,000 as of ... |
| 6/3/2022 | NeoGenomics To Participate In Multiple Upcoming Institutional Investor Conferences | neogenomics.com | FT. MYERS, FL / ACCESSWIRE / June 3, 2022 / NeoGenomics , Inc. (NASDAQ:NEO), a leading provider of cancer-focused genetic testing services and global oncology contract research services, today announced that senior management will be participating in multiple upcoming institutional investor conferences.- Management will participate in investor meetings and a presentation at the William Blair 42nd Annual Growth Stock Conference in Chicago, on Wednesday, June 8, 2022. The presentation is scheduled for ... |
| 6/3/2022 | NeoGenomics Receives CAP Certification in their Suzhou China Pharma Services Laboratory | smdailypress.com | CAP Certification Expands Global Strategic Capabilities Supporting Biopharma R&DFORT MYERS, FL / ACCESSWIRE / June 3, 2022 / NeoGenomics , Inc. (Nasdaq:NEO), a leading provider of oncology testing and global contract research services, has successfully received their CAP certification with zero deficiencies. This certification is the next step in NeoGenomics offering its global pharmaceutical partners the much-needed option to use its Suzhou laboratories for trials relating to patients in China ... |
| 6/3/2022 | NeoGenomics Receives CAP Certification in their Suzhou China Pharma Services Laboratory | inyoregister.com | CAP Certification Expands Global Strategic Capabilities Supporting Biopharma R&DFORT MYERS, FL / ACCESSWIRE / June 3, 2022 / NeoGenomics , Inc. (Nasdaq:NEO), a leading provider of oncology testing and global contract research services, has successfully received their CAP certification with zero deficiencies. This certification is the next step in NeoGenomics offering its global pharmaceutical partners the much-needed option to use its Suzhou laboratories for trials relating to patients in China ... |
| 6/3/2022 | NeoGenomics Receives CAP Certification in their Suzhou China Pharma Services Laboratory | neogenomics.com | CAP Certification Expands Global Strategic Capabilities Supporting Biopharma R&DFORT MYERS, FL / ACCESSWIRE / June 3, 2022 / NeoGenomics , Inc. (Nasdaq:NEO), a leading provider of oncology testing and global contract research services, has successfully received their CAP certification with zero deficiencies. This certification is the next step in NeoGenomics offering its global pharmaceutical partners the much-needed option to use its Suzhou laboratories for trials relating to patients in China ... |
| 6/2/2022 | NeoGenomics (NASDAQ:NEO) Shares Down 4.2% - Ticker Report | Ticker Report | ... the average daily volume of 2,242,482 shares. The stock had previously closed at $8.89.NEO has been the topic of a number of recent research reports. Cowen lowered their price target on shares of NeoGenomics from $42.00 to $24.00 and set an “outperform” rating on the stock in a research report on Tuesday, March 29th. Needham & Company LLC reduced their target price on shares of NeoGenomics from $29.00 to ... |
| 6/2/2022 | Piper Sandler Initiates Coverage on NeoGenomics (NASDAQ:NEO) - Slater Sentinel | slatersentinel.com | Equities researchers at Piper Sandler started coverage on shares of NeoGenomics ( NASDAQ:NEO – Get Rating ) in a research report issued on Thursday, The Fly reports. The firm set an “overweight” rating on the medical research company’s stock.Several other analysts have also commented on NEO. Raymond James decreased their price objective on NeoGenomics from $24.00 to $18.00 and set an “outperform” rating for the company in ... |
| 6/2/2022 | Piper Sandler Initiates Coverage on NeoGenomics (NASDAQ:NEO) | defenseworld.net | Equities researchers at Piper Sandler started coverage on shares of NeoGenomics ( NASDAQ:NEO – Get Rating ) in a note issued to investors on Thursday, The Fly reports. The brokerage set an “overweight” rating on the medical research company’s stock.Other analysts have also recently issued research reports about the stock. Morgan Stanley reduced their target price on shares of NeoGenomics from $29.00 to $27.00 and set an “equal ... |
| 6/2/2022 | Geode Capital Management LLC Buys 12,887 Shares of NeoGenomics, Inc. (NASDAQ:NEO) | Ticker Report | Geode Capital Management LLC increased NeoGenomics, Inc. ( NASDAQ:NEO – Get Rating ) by 0.6% in the 4th its most recent 13F filing with the SEC. The firm owned 2,051,612 shares of the medical research company’s stock after buying an additional 12,887 shares during the period. Geode Capital Management LLC’s holdings in NeoGenomics were worth $70,001,000 as of its most recent filing with the SEC.Several other hedge funds ... |
| 6/2/2022 | Piper Sandler Initiates Coverage on NeoGenomics (NASDAQ:NEO) | etfdailynews.com | Equities researchers at Piper Sandler started coverage on shares of NeoGenomics ( NASDAQ:NEO – Get Rating ) in a research report issued on Thursday, The Fly reports. The firm set an “overweight” rating on the medical research company’s stock.Several other analysts have also commented on NEO. Raymond James decreased their price objective on NeoGenomics from $24.00 to $18.00 and set an “outperform” rating for the company in ... |
| 6/1/2022 | Rice Hall James & Associates LLC Raises Stock Holdings in NeoGenomics, Inc. (NASDAQ:NEO) | dispatchtribunal.com | Rice Hall James & Associates LLC raised its position in shares of NeoGenomics, Inc. ( NASDAQ:NEO – Get Rating ) by 49.3% in the 4th quarter, HoldingsChannel.com reports. The institutional investor owned 83,103 shares of the medical research company’s stock after purchasing an additional 27,434 shares during the period. Rice Hall James & Associates LLC’s holdings in NeoGenomics were worth $2,835,000 as of its most recent SEC filing.Other hedge funds ... |